C4 Therapeutics (CCCC) PT Lowered to $22 at UBS
Tweet
Share
E-mailGet Alerts CCCC Hot Sheet
Price: $4.12 --0%
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 4 | New: 5
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 4 | New: 5
Join SI Premium – FREE
UBS analyst Colin Bristow lowered the price target on C4 Therapeutics (NASDAQ: CCCC) to $22.00 (from $24.00) while maintaining a Buy rating.
You May Also Be Interested In
- Morgan Stanley Upgrades QIAGEN NV (QIA:GR) (QGEN) to Overweight
- Persimmon Plc. (PSN:LN) (PSMMY) PT Lowered to GBP12.80 at Citi
- NEXON Co., Ltd (3659:JP) (NEXOF) PT Lowered to JPY2,300 at Citi
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
